戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t baseline and at 8 hours and 32 hours after typhoid vaccine.
2          Only 58 travelers (5%) had received typhoid vaccine.
3 unteers immunized with S. typhi strain Ty21a typhoid vaccine.
4 n Ty21a remains the only licensed attenuated typhoid vaccine.
5 asures, including the use of newly available typhoid vaccines.
6 ion infrastructure and the implementation of typhoid vaccines.
7  (RVV), oral cholera vaccine (OCV), and oral typhoid vaccines.
8                                          The Typhoid Vaccine Acceleration Consortium (TyVAC) aims to
9                                          The Typhoid Vaccine Acceleration Consortium (TyVAC) employs
10                         In this article, the Typhoid Vaccine Acceleration Consortium forecasts demand
11 n endemic setting in sub-Saharan Africa, the Typhoid Vaccine Acceleration Consortium is conducting a
12          In 2017, CaT joined forces with the Typhoid Vaccine Acceleration Consortium to "Take on Typh
13                                          The Typhoid Vaccine Accelerator Consortium is playing a crit
14 rain which may be useful as an improved oral typhoid vaccine and as a vector for cloned genes of othe
15 rce's assessment in light of developments in typhoid vaccines and increasing antimicrobial resistance
16 tissue tropisms, and the design for improved typhoid vaccines and therapeutics.
17 erovar Typhi strain Ty21a, the licensed oral typhoid vaccine, and genetically attenuated mutants CVD
18 e effectiveness that has not been applied to typhoid vaccines because of concerns over blood culture
19 three volunteers orally immunized with Ty21a typhoid vaccine by flow cytometry using a panel of monoc
20                  A promising live attenuated typhoid vaccine candidate strain for mucosal immunizatio
21                CVD 909 is an oral attenuated typhoid vaccine candidate that is engineered to constitu
22 aroD Delta htrA mutant), a leading live oral typhoid vaccine candidate, elicits specific CD4(+) and C
23 y2 aroC(-) ssaV(-)] ZH9) is a live oral-dose typhoid vaccine candidate.
24 e continuing evaluation of CVD 908-htrA as a typhoid vaccine candidate.
25 l model for evaluating the immunogenicity of typhoid vaccine candidates at the preclinical level.
26                                 The licensed typhoid vaccines confer only about 70 percent immunity,
27 the test-negative design core assumption for typhoid vaccine effectiveness estimation and shows the a
28       Introduction of an effective pretravel typhoid vaccine for children <2 years could reduce disea
29                                              Typhoid vaccines have been in development for >100 years
30                  Health economic analyses of typhoid vaccines have informed funding decisions and nat
31                                         Live typhoid vaccines have not elicited anti-Vi antibody, pre
32 on (WHO) to issue a revised global policy on typhoid vaccines in March 2018.
33            The current study tests whether a typhoid vaccine increases feelings of social disconnecti
34                                              Typhoid vaccine induced mild systemic inflammation at 8
35 e introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disea
36                        The Vi-rEPA conjugate typhoid vaccine is safe and immunogenic and has more tha
37 monstrating the efficacy of new Vi-conjugate typhoid vaccines is challenging, due to the cost of fiel
38                        There is currently no typhoid vaccine licensed in the United States for use in
39                                     The oral typhoid vaccine M01ZH09 is well tolerated and highly imm
40 ferential molecular signatures between the 2 typhoid vaccines, mostly driven by the upregulation in h
41  programmes, because the potential effect of typhoid vaccines on the treatment of patients with non-s
42 isms elicited by immunization with the Ty21a typhoid vaccine remains elusive.
43 ith wild-type strain Ty2, licensed live oral typhoid vaccine strain Ty21a, or attenuated serovar Typh
44 his plasmid was introduced into the licensed typhoid vaccine strain, Salmonella enterica serovar Typh
45                                          The typhoid vaccine triggered rises in both inflammatory mar
46 7D; Sanofi Pasteur, Lyon, France); live oral typhoid vaccine (Ty21a; PaxVax, London, UK), and quadriv
47  intramuscularly, left upper arm), live oral typhoid vaccine (Ty21a; PaxVax, London, UK; one capsule
48                                            A typhoid vaccine was given, and anti-typhoid antibodies w
49                                          The typhoid vaccines were associated with the most anaphylac
50                                        Prior typhoid vaccines were not suitable for use in the younge